Hodgkin’S Lymphoma

EARLY, INTERMEDIATE AND ADVANCED HODGKIN’S LYMPHOMA: MODERN TREATMENT STRATEGIES

INTRODUCTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

INTRODUCTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

STAGING ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

INTRODUCTION ,[object Object],[object Object],[object Object]

CLINICAL DIFFERENCES B/W HD & NHL HD NHL 1.Cellular derivation unresolved 90% B – cell, 10% T- cell, rarely monocytic 2.Localised to a single group of LN Involvement of multiple peripheral LN 3.Spreads by contiguity Non contiguous spread 4.Mesnteric LN & Waldeyer's ring rarely involved Commonly involved 5.Exta nodal involvement uncommon Common 6.BM involvement uncommon Common 7.Chromosomal translocation yet to be described Common 8. Curability >75% <30-40%

CLINICAL PRESENTATION ,[object Object],[object Object],[object Object],[object Object],[object Object]

ETIOLOGY ,[object Object],[object Object],[object Object],[object Object]

INVESTIGATIONS ,[object Object],[object Object],[object Object]

INVESTIGATIONS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

UNFAVORABLE FACTORS IN EARLY STAGE HD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

INTERNATIONAL PROGNOSTIC SCORE FOR ADVANCED HD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PRINCIPAL OF THERAPY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

GOAL OF THERAPY ,[object Object],[object Object],[object Object],[object Object]

RADIATION THERAPY ,[object Object],[object Object],[object Object],[object Object]

CHEMOTHERAPY ,[object Object],[object Object],[object Object],[object Object],[object Object]

SALVAGE CHEMOTHERAPY ,[object Object],[object Object],[object Object],[object Object],[object Object]

STAGE WISE MANAGEMENT ,[object Object]

INTERMEDIATE STAGE ,[object Object]

ADVANCED OR HIGH RISK DISEASE ,[object Object],[object Object],[object Object]

RELAPSED OR PRIMARY REFRACTORY DISEASE ,[object Object],[object Object]

FOLLOW UP OF PATIENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

LATE COMPLICATIONS OF THERAPY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CURRENT CLINICAL RESEARCH ,[object Object],[object Object]

FUTURE STRATEGIES FOR ADVANCED STAGE HD ,[object Object]

DO WE NEED CONSOLIDATED RADIATION? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hodgkin’S Lymphoma

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Destaque

Destaque (15)

Semelhante a Hodgkin’S Lymphoma

Semelhante a Hodgkin’S Lymphoma (20)

Último

Último (20)

Hodgkin’S Lymphoma